These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 18268093)

  • 21. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities.
    Pechtl IC; Kavanagh D; McIntosh N; Harris CL; Barlow PN
    J Biol Chem; 2011 Apr; 286(13):11082-90. PubMed ID: 21270465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations in Complement Factor H Impair Alternative Pathway Regulation on Mouse Glomerular Endothelial Cells in Vitro.
    Loeven MA; Rops AL; Lehtinen MJ; van Kuppevelt TH; Daha MR; Smith RJ; Bakker M; Berden JH; Rabelink TJ; Jokiranta TS; van der Vlag J
    J Biol Chem; 2016 Mar; 291(10):4974-81. PubMed ID: 26728463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome.
    Sánchez-Corral P; Pérez-Caballero D; Huarte O; Simckes AM; Goicoechea E; López-Trascasa M; de Córdoba SR
    Am J Hum Genet; 2002 Dec; 71(6):1285-95. PubMed ID: 12424708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complete functional characterization of disease-associated genetic variants in the complement factor H gene.
    Merinero HM; García SP; García-Fernández J; Arjona E; Tortajada A; Rodríguez de Córdoba S
    Kidney Int; 2018 Feb; 93(2):470-481. PubMed ID: 28941939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome.
    Orth D; Khan AB; Naim A; Grif K; Brockmeyer J; Karch H; Joannidis M; Clark SJ; Day AJ; Fidanzi S; Stoiber H; Dierich MP; Zimmerhackl LB; Würzner R
    J Immunol; 2009 May; 182(10):6394-400. PubMed ID: 19414792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function.
    Roumenina LT; Frimat M; Miller EC; Provot F; Dragon-Durey MA; Bordereau P; Bigot S; Hue C; Satchell SC; Mathieson PW; Mousson C; Noel C; Sautes-Fridman C; Halbwachs-Mecarelli L; Atkinson JP; Lionet A; Fremeaux-Bacchi V
    Blood; 2012 May; 119(18):4182-91. PubMed ID: 22246034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unraveling the Effect of a Potentiating Anti-Factor H Antibody on Atypical Hemolytic Uremic Syndrome-Associated Factor H Variants.
    Dekkers G; Brouwer MC; Jeremiasse J; Kamp A; Biggs RM; van Mierlo G; Lauder S; Katti S; Kuijpers TW; Rispens T; Jongerius I
    J Immunol; 2020 Oct; 205(7):1778-1786. PubMed ID: 32848031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models.
    Saunders RE; Abarrategui-Garrido C; Frémeaux-Bacchi V; Goicoechea de Jorge E; Goodship TH; López Trascasa M; Noris M; Ponce Castro IM; Remuzzi G; Rodríguez de Córdoba S; Sánchez-Corral P; Skerka C; Zipfel PF; Perkins SJ
    Hum Mutat; 2007 Mar; 28(3):222-34. PubMed ID: 17089378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation.
    Nilsson SC; Karpman D; Vaziri-Sani F; Kristoffersson AC; Salomon R; Provot F; Fremeaux-Bacchi V; Trouw LA; Blom AM
    Mol Immunol; 2007 Mar; 44(8):1835-44. PubMed ID: 17084897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family.
    Poolpol K; Orth-Höller D; Speth C; Zipfel PF; Skerka C; de Córdoba SR; Brockmeyer J; Bielaszewska M; Würzner R
    Mol Immunol; 2014 Mar; 58(1):77-84. PubMed ID: 24317278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular bases for the association of FHR-1 with atypical hemolytic uremic syndrome and other diseases.
    Martin Merinero H; Subías M; Pereda A; Gómez-Rubio E; Juana Lopez L; Fernandez C; Goicoechea de Jorge E; Martin-Santamaria S; Cañada FJ; Rodríguez de Córdoba S
    Blood; 2021 Jun; 137(25):3484-3494. PubMed ID: 33651882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome.
    Fang CJ; Fremeaux-Bacchi V; Liszewski MK; Pianetti G; Noris M; Goodship TH; Atkinson JP
    Blood; 2008 Jan; 111(2):624-32. PubMed ID: 17914026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The development of atypical hemolytic uremic syndrome depends on complement C5.
    de Jorge EG; Macor P; Paixão-Cavalcante D; Rose KL; Tedesco F; Cook HT; Botto M; Pickering MC
    J Am Soc Nephrol; 2011 Jan; 22(1):137-45. PubMed ID: 21148255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1.
    Hamad OA; Nilsson PH; Wouters D; Lambris JD; Ekdahl KN; Nilsson B
    J Immunol; 2010 Mar; 184(5):2686-92. PubMed ID: 20139276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H.
    Hebecker M; Alba-Domínguez M; Roumenina LT; Reuter S; Hyvärinen S; Dragon-Durey MA; Jokiranta TS; Sánchez-Corral P; Józsi M
    J Immunol; 2013 Jul; 191(2):912-21. PubMed ID: 23772024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries.
    Neumann HP; Salzmann M; Bohnert-Iwan B; Mannuelian T; Skerka C; Lenk D; Bender BU; Cybulla M; Riegler P; Königsrainer A; Neyer U; Bock A; Widmer U; Male DA; Franke G; Zipfel PF
    J Med Genet; 2003 Sep; 40(9):676-81. PubMed ID: 12960213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of anti-complement factor H antibodies in the development of atypical haemolytic uremic syndrome: a possible contribution to abnormality of platelet function.
    Fujisawa M; Yasumoto A; Kato H; Sugawara Y; Yoshida Y; Yatomi Y; Nangaku M
    Br J Haematol; 2020 Apr; 189(1):182-186. PubMed ID: 31879952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factor H C-Terminal Domains Are Critical for Regulation of Platelet/Granulocyte Aggregate Formation.
    Blatt AZ; Saggu G; Cortes C; Herbert AP; Kavanagh D; Ricklin D; Lambris JD; Ferreira VP
    Front Immunol; 2017; 8():1586. PubMed ID: 29218045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome.
    Ståhl AL; Sartz L; Karpman D
    Blood; 2011 May; 117(20):5503-13. PubMed ID: 21447825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome.
    Foltyn Zadura A; Zipfel PF; Bokarewa MI; Sturfelt G; Jönsen A; Nilsson SC; Hillarp A; Saxne T; Trouw LA; Blom AM
    Arthritis Res Ther; 2012 Aug; 14(4):R185. PubMed ID: 22894814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.